symbol,price,beta,volAvg,mktCap,lastDiv,range,changes,companyName,currency,cik,isin,cusip,exchange,exchangeShortName,industry,website,description,ceo,sector,country,fullTimeEmployees,phone,address,city,state,zip,dcfDiff,dcf,image,ipoDate,defaultImage,isEtf,isActivelyTrading,isAdr,isFund
AVTE,11.25,0.463685,74817,311053500,0,10.51-30.79,0.59,"Aerovate Therapeutics, Inc.",USD,0001798749,US0080641071,008064107,NASDAQ Global Market,NASDAQ,Biotechnology,https://aerovatetx.com,"Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. The company focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. Aerovate Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.",Mr. Timothy P. Noyes M.B.A.,Healthcare,US,43,617 443 2400,930 Winter Street,Waltham,MA,02116,,0,https://financialmodelingprep.com/image-stock/AVTE.png,2021-06-30,False,False,True,False,False
